Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the n‐arylpiperazines class. It features a benzothiazine motif linked via piperazine to a thiazole carboxylic acid ethyl ester. The structure incorporates several heterocycles (benzothiazine, piperazine, thiazole), which are common in medicinal chemistry for their potential bioactivity. While it has been explored as an experimental agent and is catalogued in drug discovery databases (e.g., DrugBank DB08540), there are no approved indications or clinical trials reported for this molecule. Its mechanism of action and biological targets remain uncharacterized in public sources; however, the presence of these motifs suggests possible activity on central nervous system pathways or other receptor systems relevant to neuropharmacology or related fields[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[4-(2H-1,4-benzothiazine-3-yl)-piperazine-1-yl]-1,3-thiazole-4-carboxylic acid ethylester.